Top HF news of 2019: A paradigm shift in pharmacotherapy
Click Here to Manage Email Alerts
Healio and Cardiology Today present a list of the most-read articles related to HF and transplantation published in 2019. Readers were most interested in new data that show benefit of SGLT2 inhibition in patients with HF, even in the absence of diabetes; sacubitril/valsartan for HF with preserved ejection fraction, sex-specific prevention and more.
HF pharmacotherapy in midst of paradigm shift
Dramatic results of the recent DAPA-HF and PARAGON-HF trials have prompted the cardiology community to rethink pharmacotherapy for patients with HF with reduced or preserved ejection fraction. Changes to clinical practice and to guidelines could be forthcoming, but there is a lot to sort out before that happens. Read more
DAPA-HF: Dapagliflozin offers new approach to treatment of HFrEF, even without diabetes
In patients with HF, with and without diabetes, treatment with the SGLT2 inhibitor dapagliflozin reduced risk for worsening HF and CV death when added to standard therapy, according to anticipated results of the DAPA-HF trial presented at the European Society of Cardiology Congress. Read more
PARAGON-HF: Sacubitril/valsartan misses primary endpoint for HFpEF; may still provide insight into unmet need
Sacubitril/valsartan did not reduce the rate of hospitalizations for CV-related death and HF in patients with HF with preserved ejection fraction, defined as at least 45%, according to a hot line trial presented at the European Society of Cardiology Congress.
Out of the loop: Augmenting diuresis with SGLT2 inhibitors in HF
The Cardiology Today July 2019 Pharmacology Consult focuses on diuresis with SGLT2 inhibitors in patients with HF. Read more
Women may particularly benefit from sex-specific HF prevention
Sex-specific prevention strategies are critical in the presence of different HF risk factors and mechanisms in men and women, according to a review published in JACC: Heart Failure. Read more
Vitamin D, fish oil fail to reduce first HF hospitalization risk
Interventions with vitamin D or omega-3 failed to reduce rates of first heart failure hospitalization in a large cohort of healthy adults, although researchers observed a benefit for recurrent HF hospitalization with fish oil supplementation, according to findings from an ancillary study of the VITAL trial presented at the American Heart Association Scientific Sessions. Read more
EMPERIAL top-line results: Empagliflozin for HFpEF, HFrEF fails to improve exercise ability
Boehringer Ingelheim and Eli Lilly and Co. announced negative top-line results for its EMPERIAL-Reduced and EMPERIAL-Preserved trials, noting that the SGLT2 inhibitor empagliflozin did not meet the primary endpoint of improvements in exercise ability according to the 6-minute walk test from baseline to 12 weeks compared with placebo in patients with chronic HF with reduced and preserved ejection fraction. Read more
PRIME: Sacubitril/valsartan reduces mitral regurgitation
Sacubitril/valsartan reduced mitral regurgitation to a greater extent than valsartan alone in patients with HF and chronic functional mitral regurgitation, according to findings published in Circulation. Read more
DEFINE-HF: Dapagliflozin improves HF-related health regardless of diabetes status
In patients with HF with reduced ejection fraction with or without diabetes, dapagliflozin was associated with clinically meaningful improvements in HF-related health status or N-terminal pro-B type natriuretic peptide at 12 weeks, according to results of the DEFINE-HF trial presented at the Heart Failure Society of America Scientific Meeting. Read more